Диссертация (1139442), страница 53
Текст из файла (страница 53)
Яненко, Д.С. Меринов, О.В.Константинова // Экспериментальная и клиническая урология. – 2012. – № 3.– С. 19-25.245. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostatecancer / F.C. Hamdy [et al.] // N. Engl. J. Med. – 2016. – N 375. – Р. 1415-1424.246. A community based study of prostatic symptoms in Singapore / H.Y. Tan [et al.] //J. Urol.
– 1997. – Vol. 157, N 3. – P. 890-893.247. A pragmatic randomized controlled trial examining the impact of the Retziussparing approach on early urinary continence recovery after robot-assisted radicalprostatectomy / D. Dalela [et al.] // Eur. Urol. – 2017. – N 72. – Р. 677-685.248. A risk calculator for prostate cancer risk 4 years after negative screening findings:ERSPC Rotterdam / M.J.
Roobol [et al.] // 27th Annual EAU Congress:compilation of abstracts. – Paris, France, 2012 – P. 145-145.249. A risk-based strategy improves prostate-specific antigen-driven detection ofprostate cancer / M.J. Roobol [et al.] // Eur. Urol. – 2010. – Vol. 57, N 1. – P. 7985.250. Andersson K.E. Treatment of lower urinary tract symptoms: agents forintraprostatic injection / K.E. Andersson // Scand. J. Urol.
– 2013. – N 47. – Р. 8390.251. Annual report on status of cancer in China / W. Chen [et al.] // Chin. J. Cancer.Res. – 2015. – Vol. 27, N 1. – P. 2-12.252. Assessing individual risk for prostate cancer / R.K. Nam [et al.] // J. Clin. Oncol. –2007. – Vol. 25, N 24. – P. 3582-3588.253. Benign prostatic hyperplasia and lower urinary tract symptoms: research priorities/ C. De Nunzio [et al.] // Eur. Urol. – 2011. – Vol. 60, N 6. – P. 1205-1206.254. Benign prostatic hyperplasia in elderly Thai men in an urban community: theprevalence, natural history and health related behavior / А. Tantiwong [et al.] // J.Med.
Assoc. Thai. – 2002. –Vol. 85, N 3. – P. 356-360.255. Berkowitz B. Rural public health service deriver promising new directions / B.Berkowitz // Fm. J. Public Health. – 2004. – Vol. 94, N 10. – P. 1678-168.256. Beyond the learning curve of the Retzius-sparing approach for robot-assistedlaparoscopic radical prostatectomy: oncologic and functional results of the first291200 patients with ≥ 1 year of follow-up / А. Galfano [et al.] // Eur. Urol. – 2013. –N 64. – Р. 974-980.257. Brener Z.Z. Nephrolithiasis: evaluation and management / Z.Z. Brener // SouthMed.
J. – 2011. – Vol. 104, Suppl. 2. – P. 133-139.258. Can the prostate risk calculator based on Western population be applied to Asianpopulation? / D.K. Yoon [et al.] // Prostate. – 2012. – Vol. 72, N 7. – P. 721-729.259. Cancer incidence among Korean-American immigrants in the United States andnative Koreans in South Korea / J. Lee [et al.] // Cancer Control. – 2007. – Vol. 14,N 1. – P. 78-85.260. Comparison of risk calculators from the Prostate Cancer Prevention Trial and theEuropean Randomized Study of Screening for Prostate Cancer in a contemporaryCanadian cohort / G. Trottier [et al.] // BJU Int.
– 2011. – Vol. 108, N 8. – P. 237244.261. Compliance with biopsy recommendations of a prostate cancer risk calculator /H.A. Van Vugt [et al.] // BJU Int. – 2012. – Vol. 109, N 10. – P. 1480-1488.262. Cost-effectiveness of prostate cancer screening: a simulation study based onERSPC data [еlectronic resource] / E.A. Heijnsdijk [et al.] // J. Natl. Cancer. Inst. –2014.
– Vol. 107, N 1. – URL : http://www.ncbi.nlm.nih.gov/pubmed/25505238.263. Critical review of guidelines for BPH diagnosis and treatment strategy / G. Novara[et al.] // Eur. Urol. Suppl. – 2006. – Vol. 5. – P. 418-29.264. Day S.H. Board certification: the global perspective / S.H. Day // Ophthalmology.– 2016. – Vol. 123, N 9. – P.
50-4.265. Detection of high-grade prostate cancer using a urinary molecular biomarker-basedrisk score / L. Van Neste [et al.] // Eur. Urol. – 2016. – N 70. – Р. 740–748.266. Diagnosis of prostate cancer: The Clinical use of transrectal ultrasound and biopsy/ B. Djavan [et al.] // EAU Update Series. – 2003. – N 1. – P. 9-15.267. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer(PROMIS): a paired validating confirmatory study / H.U.
Ahmed [et al.] // Lancet.– 2017. – N 389. – Р. 815-822.268. Diagnostic performance of PCA3 to detect prostate cancer in men with increasedprostate specific antigen: a prospective study of 1,962 cases / E.D. Crawford [etal.] // J. Urol. – 2012. – N 188. – Р. 1726-1731.292269. Disease-specific survival of men with prostate cancer detected during the screeninginterval: results of the European randomized study of screening for prostate cancerRotterdam after 11 years of follow-up / X. Zhu [et al.] // Eur. Urol. – 2011. – Vol.60, N 2.
– P. 330-336.270. Do prostate cancer risk models improve the predictive accuracy of PSA screening?A meta-analysis [еlectronic resource] / K.S. Louie [et al.] // Ann. Oncol. – 2014. –URL: http://www.ncbi.nlm.nih.gov/pubmed/25403590.271. Does physical activity reduce the risk of prostate cancer? A systematic review andmeta-analysis / Y. Liu [et al.] // Eur. Urol. – 2011. – Vol. 60, N 5.
– P. 1029–1044.272. Donabedian A. – The Criteria and Standards of Quality / A. Donabedian // JAMA.– 1988. – Vol. 260. – P.1743 – 1748.273. Donabedian A. Explorations in Quality Assessment and Monitoring / A.Donabedian. – Mich: Health Administration Press. – 1982.
– 251p.274. Donabedian A. Explorations in Quality Assessment and Monitoring / A.Donabedian // The Definition of Quality and Approaches to Its Assessment–Michigan: Health Administration Press, 1980. – Vol. 1. 457 p.275. Donabedian A. The Methods and Findings of Quality Assessment and Monitoring /A. Donabedian. – Michigan: Health Administration Press. 1985. – 900 p.276. Donabedian A.
The quality of medical care methods for assessing and monitoringthe quality of care for research and for quality assurance programs / A. Donabedian// Science. – 1978. – Vol. 200. – P. 856-864.277. Economic evaluation of prostate cancer screening test as a national cancerscreening program in South Korea / S.
Shin [et al.] // Asian. Pac. J. Cancer. Prev. –2014. – Vol. 15, N 8. – P. 3383-3389.278. Effect of metabolic syndrome and its components on prostate cancer risk: metaanalysis / K. Esposito [et al.] // J. Endocrinol. Invest. – 2013. – Vol. 36, N 2. – P.132-139.279. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia usingthe international prostate symptom score / Y. Homma [et al.] // Int.
J. Urol. – 1997.– Vol. 4, N 1. – P.40-46.280. Epidemiologic survey on urination / Y. Homma [et al.] // Journal of NeurogenicBladder Society. – 2003. – Vol. 14. – P. 266-277.293281. Epidemiology and natural history of benign prostatic hyperplasia. Male LowerUrinary Tract Symptoms. Evaluation and Management. 6th InternationalConsultation on Prostate Cancer and Prostatic Diseases / J. McConnell [et al.] //Paris, France: Health Publications.
– 2006. – P. 37-53.282. Epidemiology of prostate cancer: current status / Z.Q. Tao [et al.] // Eur. Rev. Med.Pharmacol. Sci. – 2015. – Vol. 19, N 5. – P. 805-812.283. Epidemiology of urolithiasis for improving clinical practice / T. Yasui [et al.] //Hinyokika Kiyo. – 2012. – Vol. 58, N 12. – P. 697-701.284.
Evaluation of the activity of a urological emergency unit in university hospital / L.Martin [et al.] // Prog. Urol. – 2014. – Vol. 24, N 1. – P. 62-66.285. External validation of the Risk indicator®. ERSPC Rotterdam, Helsinki andTampere / M.J. Roobol [et al.] // Eur. Urol. Suppl. – 2009. – Vol. 8, N 4. – P. 192.286.
Failure to follow-up test results for ambulatory patients: a systematic review / J.L.Callen [et al.] // J. Gen. Intern. Med. –2011. – Vol. 274. – P. 1334-1348.287. Familial risk and heritability of cancer among twins in Nordic countries / L.A.Mucci [et al.] // JAMA. – 2016. – N 315. – Р. 68-76.288. First-year costs of treating prostate cancer: estimates from SEER-Medicare data /C.G. Roehrborn [et al.] // Prostate. Cancer. Prostatic. Dis.
– 2009. – Vol. 12, N 4. –P. 355-360.289. Flam T. Screening of clinical benign prostatic hypertrophy in general practice:survey of 18,540 men / Т. Flam, V. Montauban // Prog. Urol. – 2003. – Vol. 13, N3. – P. 416-424.290. Franks L.M. Latent carcinoma / L.M.
Franks // Ann. R. Coll. Surg. Engl. – 1954. –Vol. 15, N 4. – P. 236-249.291. Garraway W.M. High prevalence of benign prostatic hypertrophy in thecommunity / W.M. Garraway, G.N. Collins, R.J. Lee // Lancet. – 1991. – Vol. 338.– P. 469-471.292. Gathirua-Mwangi W.G. Dietary factors and risk for advanced prostate cancer /W.G. Gathirua-Mwangi, J.
Zhang // Eur. J. Cancer. Prev. – 2014. – Vol. 23, N 2. –P. 96-109.293. Global Cancer Statistics, 2012 / L.A. Torre [et al.] // Cancer. J. Clin. – 2015. – Vol.65, N 2. – P. 87-108.294294. Global patterns of prostate cancer incidence, aggressiveness, and mortality in menof African descent [Electronic resource] / T.R. Rebbeck [et al.] // Prostate Cancer.– 2013. – URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583061.295.
GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalenceworldwidein2012[еlectronicresource]–URL:http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.296. Gu F. Changes in the prevalence of benign prostatic hyperplasia in China / F. Gu //Chin. Med. J. – 1997. – Vol. 110, N 3. – P. 163-166.297. Gu F. Epidemiological survey of benign prostatic hyperplasia and prostatic cancerin China / F. Gu // Chin. Med. J. – 2000. – Vol. 113, N 4. – P.
299-302.298. Hamashima C. Cost-effectiveness analysis of prostate cancer screening / C.Hamashima, K. Yoshida // Environ. Health. Prev. Med. – 2000. – Vol. 5, N 3. – P.111-117.299. Immediate versus delayed radical prostatectomy: updated outcomes followingactive surveillance of prostate cancer / Р. Filippou [et al.] // Eur. Urol. – 2015. – N68. – Р. 458-463.300. Importance of prostate volume in the European Randomised Study of Screeningfor Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsycollaborative group / M.J. Roobol [et al.] // World. J. Urol. – 2012. – Vol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
